{
  "symbol": "MO",
  "year": 2024,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.184,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.136
  },
  "top_positive": [
    {
      "sent": "43 Table of Contents The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the nine months ended September 30: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2024 Reported $ 10,881 $ 2,656 $ 8,225 $ 4.75 NPM Adjustment Items (27) (7) (20) (0.01) Acquisition, disposition and integration-related items (2,513) (664) (1,849) (1.07) Asset impairment 354 90 264 0.15 Tobacco and health and certain other litigation items 90 22 68 0.04 ABI-related special items (39) (9) (30) (0.01) Cronos-related special items 22 2 20 0.01 Income tax items \u2014 41 (41) (0.02) 2024 Adjusted for Special Items $ 8,768 $ 2,131 $ 6,637 $ 3.84 2023 Reported $ 8,193 $ 2,123 $ 6,070 $ 3.40 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 14 4 10 \u2014 Tobacco and health and certain other litigation items 424 106 318 0.18 Loss on disposition of JUUL equity securities 250 \u2014 250 0.14 ABI-related special items 54 11 43 0.02 Cronos-related special items 30 \u2014 30 0.02 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 8,950 $ 2,211 $ 6,739 $ 3.78 The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the three months ended September\u00a030: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2024 Reported $ 3,026 $ 733 $ 2,293 $ 1.34 NPM Adjustment Items (21) (6) (15) (0.01) Acquisition, disposition and integration-related items 44 11 33 0.02 Tobacco and health and certain other litigation items 22 6 16 0.01 ABI-related special items 23 5 18 0.01 Cronos-related special items 2 1 1 \u2014 Income tax items \u2014 (11) 11 0.01 2024 Adjusted for Special Items $ 3,096 $ 739 $ 2,357 $ 1.38 2023 Reported $ 2,908 $ 742 $ 2,166 $ 1.22 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 13 4 9 \u2014 Tobacco and health and certain other litigation items 23 6 17 0.01 ABI-related special items 82 17 65 0.03 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 3,011 $ 736 $ 2,275 $ 1.28 The following special items affected the comparability of statements of earnings amounts for the nine and three months ended September 30, 2024 and 2023: \u25aa NPM Adjustment Items: For a discussion of NPM Adjustment Items and a breakdown of these items by segment, see Health Care Cost Recovery Litigation in Note 14 and NPM Adjustment Items in Note 11, respectively.",
      "score": 0.9903
    },
    {
      "sent": "43 Table of Contents The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the nine months ended September 30: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2024 Reported $ 10,881 $ 2,656 $ 8,225 $ 4.75 NPM Adjustment Items (27) (7) (20) (0.01) Acquisition, disposition and integration-related items (2,513) (664) (1,849) (1.07) Asset impairment 354 90 264 0.15 Tobacco and health and certain other litigation items 90 22 68 0.04 ABI-related special items (39) (9) (30) (0.01) Cronos-related special items 22 2 20 0.01 Income tax items \u2014 41 (41) (0.02) 2024 Adjusted for Special Items $ 8,768 $ 2,131 $ 6,637 $ 3.84 2023 Reported $ 8,193 $ 2,123 $ 6,070 $ 3.40 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 14 4 10 \u2014 Tobacco and health and certain other litigation items 424 106 318 0.18 Loss on disposition of JUUL equity securities 250 \u2014 250 0.14 ABI-related special items 54 11 43 0.02 Cronos-related special items 30 \u2014 30 0.02 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 8,950 $ 2,211 $ 6,739 $ 3.78 The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the three months ended September\u00a030: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2024 Reported $ 3,026 $ 733 $ 2,293 $ 1.34 NPM Adjustment Items (21) (6) (15) (0.01) Acquisition, disposition and integration-related items 44 11 33 0.02 Tobacco and health and certain other litigation items 22 6 16 0.01 ABI-related special items 23 5 18 0.01 Cronos-related special items 2 1 1 \u2014 Income tax items \u2014 (11) 11 0.01 2024 Adjusted for Special Items $ 3,096 $ 739 $ 2,357 $ 1.38 2023 Reported $ 2,908 $ 742 $ 2,166 $ 1.22 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 13 4 9 \u2014 Tobacco and health and certain other litigation items 23 6 17 0.01 ABI-related special items 82 17 65 0.03 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 3,011 $ 736 $ 2,275 $ 1.28 The following special items affected the comparability of statements of earnings amounts for the nine and three months ended September 30, 2024 and 2023: \u25aa NPM Adjustment Items: For a discussion of NPM Adjustment Items and a breakdown of these items by segment, see Health Care Cost Recovery Litigation in Note 14 and NPM Adjustment Items in Note 11, respectively.",
      "score": 0.9903
    },
    {
      "sent": "43 Table of Contents The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the nine months ended September 30: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2024 Reported $ 10,881 $ 2,656 $ 8,225 $ 4.75 NPM Adjustment Items (27) (7) (20) (0.01) Acquisition, disposition and integration-related items (2,513) (664) (1,849) (1.07) Asset impairment 354 90 264 0.15 Tobacco and health and certain other litigation items 90 22 68 0.04 ABI-related special items (39) (9) (30) (0.01) Cronos-related special items 22 2 20 0.01 Income tax items \u2014 41 (41) (0.02) 2024 Adjusted for Special Items $ 8,768 $ 2,131 $ 6,637 $ 3.84 2023 Reported $ 8,193 $ 2,123 $ 6,070 $ 3.40 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 14 4 10 \u2014 Tobacco and health and certain other litigation items 424 106 318 0.18 Loss on disposition of JUUL equity securities 250 \u2014 250 0.14 ABI-related special items 54 11 43 0.02 Cronos-related special items 30 \u2014 30 0.02 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 8,950 $ 2,211 $ 6,739 $ 3.78 The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the three months ended September\u00a030: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2024 Reported $ 3,026 $ 733 $ 2,293 $ 1.34 NPM Adjustment Items (21) (6) (15) (0.01) Acquisition, disposition and integration-related items 44 11 33 0.02 Tobacco and health and certain other litigation items 22 6 16 0.01 ABI-related special items 23 5 18 0.01 Cronos-related special items 2 1 1 \u2014 Income tax items \u2014 (11) 11 0.01 2024 Adjusted for Special Items $ 3,096 $ 739 $ 2,357 $ 1.38 2023 Reported $ 2,908 $ 742 $ 2,166 $ 1.22 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 13 4 9 \u2014 Tobacco and health and certain other litigation items 23 6 17 0.01 ABI-related special items 82 17 65 0.03 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 3,011 $ 736 $ 2,275 $ 1.28 The following special items affected the comparability of statements of earnings amounts for the nine and three months ended September 30, 2024 and 2023: \u25aa NPM Adjustment Items: For a discussion of NPM Adjustment Items and a breakdown of these items by segment, see Health Care Cost Recovery Litigation in Note 14 and NPM Adjustment Items in Note 11, respectively.",
      "score": 0.9903
    }
  ],
  "top_negative": [
    {
      "sent": "(4) Includes as of October 28, 2024, one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms \u201cLights\u201d and \u201cUltra Lights\u201d constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.",
      "score": -0.9517
    },
    {
      "sent": "(4) Includes as of October 28, 2024, one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms \u201cLights\u201d and \u201cUltra Lights\u201d constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.",
      "score": -0.9517
    },
    {
      "sent": "Cases: Claims related to tobacco products generally fall within the following categories: (i)\u00a0smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii)\u00a0health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iii) e-vapor cases alleging violation of RICO, fraud, failure to warn, design defect, negligence, antitrust, patent infringement and unfair trade practices; and (iv)\u00a0other tobacco-related litigation described below.",
      "score": -0.9274
    }
  ],
  "forward_snippets": [
    "This guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value.",
    "This guidance also specifies required disclosures for equity securities subject to contractual sale restrictions.",
    "For a description of issued accounting guidance applicable to, but not yet adopted by, us, see Note 15.",
    "New Accounting Guidance Not Yet Adopted .",
    "This guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value."
  ]
}